Could Reformed HTA Be A Legacy Of COVID-19?
Executive Summary
The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?
You may also be interested in...
Older Medicines Rebate Will Test UK’s New Pricing & Access Scheme
As the UK government implements a new rebate system for older medicines as part of the new pricing deal, industry trade bodies and experts suggest that exceptions will have to be made, such as higher prices or lower rebate levels for specific products.
Pressure Mounts For Agreement On New UK Voluntary Pricing Scheme
With the clock ticking on UK drug pricing negotiations, it is still unclear whether even high-level terms of a new voluntary deal will be agreed in time.
Industry Calls For Reform of England’s Unused Innovative Medicines Fund
The pharmaceutical industry says financial uncertainties are a key reason why the English Innovative Medicines Fund (IMF) – offering the potential for time-limited funding for promising non-cancer treatments where benefits are uncertain at launch - has still not been used a year after it was put in place. Industry wants the National Health Service to share the financial risk of taking part in the fund.